

October 21, 2025

3Q25 earnings period started yesterday before market opening with Türkiye Sigorta

TAVHL, AKBNK and ANHYT are expected to release their results on October 23, followed by ARCLK and ANSGR on October 24. The deadline for non-financial companies and insurance firms to disclose their unconsolidated financial results is October 30, while the deadline for submitting consolidated financial results is November 10. For 3Q25, we expect a substantial 64% y/y increase in financial sector's earnings, while we forecast a limited 3% y/y expansion for non-financials.

Banking sector earnings quality should improve in 3Q

The earnings season for banks will kick off with Akbank on October 23, followed by Garanti and Yapı Kredi. We expect the banks under our coverage to post a quarterly earnings growth of only 2%, but a strong annual increase of 66% in 3Q25. Core revenues may rise by 25% q/q in 3Q, supported by a widening TL loan-to-deposit spread, upward revisions to October CPI expectations, and increased merchant commission income. The loan-to-deposit spread is expected to support core revenues due to declining funding costs in 3Q. The swap-adjusted net interest margin could expand by 79 basis points q/q. Swap costs may rise by 54% q/q, as TL swap rates are lower than TL deposit costs, making swaps more attractive to banks. Fee income is anticipated to grow by 51% y/y (and 10% q/q), supported by new loan disbursements and payment system contributions. The fee-to-operating-expense ratio is expected to gradually normalize below the 100% level. Operating expenses may remain under pressure due to mid-year salary hikes and high inflation, growing by 43% y/y (14% q/q). Income from subsidiaries and collections may not sufficiently support other banking income compared to the previous quarter. Net total credit risk cost is expected to increase by 9 basis points QoQ to reach 200 basis points, due to a limited deterioration in asset quality. Return on equity (ROE) is likely to remain flat at around 22%, in line with the previous quarter. We expect **AKBNK** and **YKBNK** to deliver stronger profitability among the banks under our coverage in 3Q. On the other hand, **YKBNK** and **ISCTR** are expected to lead in annual profitability performance compared to their peers.

Annual profitability growth looks strong for insurance companies

While the 2.5-point decline in the discount rate for non-life insurers may dampen excitement on a quarterly basis, we believe annual profitability performance will be more promising. **ANHYT** and **AGESA** may stand out with strong potential for annual profit growth, driven by solid life premium production and robust pension asset growth.

Non-financial companies' 3Q net profit should post a limited 3% increase y/y

Overall, the macroeconomic environment remained weak throughout the third quarter. In 3Q25, tight financial conditions weighed on companies financials. Due to weak demand, companies were unable to fully reflect rising production costs in their prices. In terms of y/y net profit growth, **TOASO** and **DOAS** are expected to be the top performers among non-financial companies with positive 3Q25 net profits. They are expected to be followed by **GWIND** and **TABGD**. In contrast, we anticipate declines in net profits of **TTRAK**, **TCELL** (3Q24 income has one-off gain), **MGROS**, **MPARK** (3Q24 income has one-off gain), and **FROTO**. While **TOASO** is showing growth driven by the Stellantis merger, margins may continue to be under pressure. For **DOAS**, we anticipate strong y/y growth in net profit due to a low base effect. It is worth noting that **TCELL**'s 3Q24 net profit includes a one-off gain from the sale of its Ukraine operations. Thanks to effective cost management, we expect strong operational profitability for **MPARK**, while also reminding that there was a one-off income in 3Q24 net profit due to negative goodwill. For **ASELS**, we expect the strong backlog and operational profitability to continue in 3Q25. We believe **GWIND** will stand out due to increased electricity production and improved financing costs.

For EBITDA, we forecast a 12% y/y increase for non-financial companies

In terms of annual EBITDA growth, **TOASO**, **TAVHL**, **ARCLK**, **BIMAS** and **TCELL** are expected to deliver the strongest performances within our coverage. On the other hand, **DOAS**, **FROTO**, and **TTRAK** are likely to post y/y contraction in EBITDA in 3Q25.

3Q25E Earnings Preview (TLmn)


	3Q25	3Q24	y/y	2Q25	q/q
Non Financials					
Revenues	1,556,604	1,450,910	7%	1,469,318	6%
EBITDA	213,401	191,153	12%	180,388	18%
Net Income	120,840	117,199	3%	81,612	48%
Financials*					
Net Income	81,118	49,376	64%	79,765	2%

	3Q25	3Q24	y/y	2Q25	q/q
USDTRY					
period end	41.51	34.12	22%	39.74	4%
average	40.71	33.47	22%	38.70	5%
EURTRY					
period end	48.75	38.17	28%	46.61	5%
average	47.57	36.76	29%	43.92	8%


Source: OYAK Securities Estimates, Datastream , *Banks plus insurance companies

3Q25E Top & Worst Performers Among Non-Financials (TL)


Revenue growth- Y/Y




Revenue growth- Q/Q




Ebitda growth-Y/Y




Ebitda growth-Q/Q



Net income growth-Y/Y



Net income growth-Q/Q



Source: OYAK Securities Estimates, base impact, inorganic expansion, divestitures, one-offs and seasonality may have impact on Y/Y and Q/Q changes.

Summary of Coverage Universe (TLmn)

Financials											Net Income				
Banks											3Q25E	3Q24	2Q25	y/y	q/q
AKBNK											13,891	9,031	11,125	54%	25%
GARAN											28,528	22,095	28,326	29%	1%
ISCTR											14,211	5,534	17,372	157%	-18%
YKBNK											13,111	5,001	11,330	162%	16%
ALBRK											729	794	1,256	-8%	-42%
Insurance											3Q25E	3Q24	2Q25	y/y	q/q
ANHYT											1,396	707	1,326	97%	5%
AGESA											1,260	702	1,260	79%	0%
ANSGR											3,285	2,441	2,959	35%	11%
Non-financials															
	Revenues					EBITDA					Net Income				
	3Q25E	3Q24	2Q25	y/y	q/q	3Q25E	3Q24	2Q25	y/y	q/q	3Q25E	3Q24	2Q25	y/y	q/q
AKSEN	10,547	10,930	10,602	-4%	-1%	2,764	2,286	2,701	21%	2%	1,107	881	999	26%	11%
ARCLK	125,171	140,479	130,471	-11%	-4%	8,762	6,183	7,606	42%	15%	-1,415	-6,667	-2,511	-79%	-44%
AELS	31,719	29,073	31,768	9%	0%	7,784	6,565	8,617	19%	-10%	2,791	2,671	4,293	4%	-35%
BIMAS	179,283	167,867	164,739	7%	9%	10,244	7,243	10,131	41%	1%	4,587	5,800	2,895	-21%	58%
CCOLA	51,890	48,933	51,755	6%	0%	11,303	9,900	9,746	14%	16%	7,170	6,895	5,430	4%	32%
DOAS	54,350	50,556	64,653	8%	-16%	3,308	2,957	4,240	12%	-22%	1,255	374	2,275	236%	-45%
FROTO	185,429	188,916	209,411	-2%	-11%	11,218	12,954	13,551	-13%	-17%	7,649	11,413	6,569	-33%	16%
GWIND	953	823	650	16%	47%	667	584	449	14%	48%	319	202	291	58%	10%
KCHOL				n.m.	n.m.				n.m.	n.m.	8,705	-4,908	8,313	n.m.	5%
KLKIM	2,530	2,492	2,560	2%	-1%	582	607	600	-4%	-3%	329	321	349	2%	-6%
MPARK	12,857	13,039	12,762	-1%	1%	3,721	3,492	3,114	7%	19%	1,572	2,787	1,123	-44%	40%
MGROS	105,740	99,286	98,577	7%	7%	8,212	7,578	5,371	8%	53%	2,162	4,204	302	-49%	616%
OTKAR	9,048	9,721	12,256	-7%	-26%	103	-151	1,549	n.m.	-93%	-385	-1,205	443	-68%	n.m.
* PGSUS	53,110	40,082	38,425	33%	38%	18,368	16,037	12,822	15%	43%	8,998	10,824	5,132	-17%	75%
SAHOL				n.m.	n.m.				n.m.	n.m.	893	-3,754	1,883	n.m.	-53%
SELEC	39,701	39,543	38,816	0%	2%	787	1,294	689	-39%	14%	-163	273	-346	n.m.	-53%
* TAVHL	25,967	18,358	19,546	41%	33%	10,241	7,205	6,439	42%	59%	3,099	3,821	-192	-19%	n.m.
TABGD	11,752	10,684	11,947	10%	-2%	2,604	2,442	2,685	7%	-3%	874	719	1,220	22%	-28%
TCELL	59,019	50,976	54,069	16%	9%	25,961	21,843	25,149	19%	3%	5,028	19,035	4,516	-74%	11%
* THYAO	281,741	221,815	231,324	27%	22%	63,302	59,088	46,071	7%	37%	52,963	51,540	26,831	3%	97%
TOASO	90,179	28,588	74,651	215%	21%	2,841	354	2,601	702%	9%	1,438	416	1,882	246%	-24%
TTRAK	11,272	17,195	13,427	-34%	-16%	1,139	2,694	1,325	-58%	-14%	305	1,235	364	-75%	-16%
TUPRS	214,346	261,553	196,909	-18%	9%	19,489	19,999	14,932	-3%	31%	11,558	10,322	9,550	12%	21%

Source: OYAK Securities Estimates, Datastream, 3Q24 and 2Q25 are indexed with in accordance to IAS-29, *excl. inflation accounting and EBITDA is unadjusted

Oyak Securities

Equity Research

Övünç Gürsoy, PhD, CFA	Strategy, Banks, Insurance, Real Estate	ovunc.gursoy@oyakyatirim.com.tr +90 (212) 319 12 13
Melis Pocar	Food and Beverage, Retail, Aviation	melis.pocar@oyakyatirim.com.tr +90 (212) 319 12 15
Yusuf Ekvuran	Automotive, Defence, Telecom, Healthcare, White Goods, Glass, Mining	yusuf.ekvuran@oyakyatirim.com.tr +90 (212) 319 12 14
Özgür Fedai Durmaz	Conglomerates, Oil and Gas, Chemicals, Energy, Steel	ozgur.durmaz@oyakyatirim.com.tr +90 (212) 319 12 18
Alper Topkaya	Economist	alper.topkaya@oyakyatirim.com.tr +90 (212) 319 12 09

Institutional Sales & Trading

Osman Ozvural	Senior Director	osman.ozvural@oyakyatirim.com.tr +90 (212) 319 12 20
Selin Pekçe	Director	selin.pekce@oyakyatirim.com.tr +90 (212) 319 12 30

Disclaimer

The information, comments and advices included herein do not constitute an offer or a solicitation of an offer to buy or sell any securities. The matters covered on this report may include forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. OYAK Yatırım Menkul Değerler A.Ş. ("OYAK Securities"), does not undertake to advise you of changes in the information or opinions set forth herein or provide you with access to any additional information or to correct any inaccuracies therein which may become apparent subsequent to the date hereof or to publicly update any information or any forward looking statement, whether as a result of new information, future events or otherwise. Content and information provided by third parties is published as supplied to OYAK Securities and OYAK Securities has not independently verified any of such information.

The investment information, comments and advices given herein are not part of investment advisory activity. Investment advisory services are provided by authorized institutions to persons and entities privately by considering their risk and return preferences. Whereas the comments and advices included herein are of general nature. Therefore, they may not be appropriate for your financial situation and risk and return preferences. For this reason, making an investment decision solely by relying on the information given herein may not give rise to results within your expectations. Investors should not make their investment decisions on the basis of this report and construe the contents of this report as legal, tax, financial or investment advice.

OYAK Securities, any of its parents, subsidiaries or affiliates, agents, employees or representatives, do not make any representations or warranties, express or implied, for the accuracy, timeliness, completeness or fairness of any such information or any estimates, conclusions or opinions based thereon, and does not accept any liability or responsibility whatsoever for the contents of the report or for any errors, omissions or mis-statements or for any adverse consequences of the investment decisions made as a result of reliance upon this report.

OYAK Securities, any of its parents, subsidiaries or affiliates, agents, employees or representatives may hold positions and execute transactions in securities of entities mentioned in the document. In addition, OYAK Securities, any of its parents, subsidiaries or affiliates, agents, employees or representatives might have, might be seeking or will seek investment banking or other business relationships with the companies in this report.

Copyright in this report is owned by OYAK Securities except where otherwise indicated by a third party's proprietary notice and may not be reproduced or appropriated in any manner without written permission of OYAK Securities or their respective owners.

Valuation Approach

Valuation tools employed most frequently are Discounted Cash Flow (DCF) and International Peer Group Comparison, though other metrics such as Dividend Discount, Gordon Growth, and Replacement Value Methods are also used wherever appropriate. Oyak Securities analysts may calculate the target return of each stock considering only one method or assigning different weights to more than one method depending on the analyst's opinion. The "Expected Market Return" (EMR) of the BIST-100 is determined through aggregate target returns of each stock under coverage based on their respective free float market capitalization.

Rating Methodology

Oyak Securities assigns recommendations to each stock according to the following criteria:

Price target for a stock represents the value analyst expects the stock to reach during our performance horizon, which is 12 months. For stocks with an OUTPERFORM recommendation, target return must exceed the EMR by at least 40% over the next 12 months. For a stock to be classified as UNDERPERFORM, the stock must be expected to underperform the EMR more than 25% over the next 12 months. Stocks that an analyst expects to perform parallel to the EMR within a band of +40%/-25% are rated as MARKETPERFORM. Oyak Securities analysts review their recommendations under continuous screening. Nevertheless, at times, target return of a stock may be allowed to move outside our rating intervals as a result of share price fluctuations. Under such circumstances, the analyst may choose not to change his/her recommendation.